Summary
FIXX Chart
Homology Medicines Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kerr Financial Planning Corp Kerr Financial Planning Corp | 600 | $1 | $1 | - | - |
Homology Medicines Inc (FIXX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Homology Medicines Inc Profile
| Biotechnology Industry | Healthcare Sector | Paul Alloway CEO | NASDAQ (NGS) Exchange | 438083107 CUSIP |
| US Country | 7 Employees | - Last Dividend | 25 Mar 2024 Last Split | 28 Mar 2018 IPO Date |
Overview
Homology Medicines, Inc. is a pioneering genetic medicines company dedicated to transforming the lives of patients afflicted by rare genetic diseases primarily in the United States. Founded in 2015 and based in Bedford, Massachusetts, the company has positioned itself at the forefront of genetic medicine with a focus on in vivo treatments utilizing its unique human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs). These vectors are employed to deliver cutting-edge genetic therapies, including nuclease-free gene editing and gene therapy techniques, targeting a variety of genetic disorders. Homology Medicines stands out for its innovative approach to treating rare genetic diseases, leveraging the natural properties of AAVHSCs to provide potentially curative therapies.
Products and Services
- HMI-202
- HMI-104
This investigational gene therapy has completed its IND (Investigational New Drug)-enabling studies for the treatment of metachromatic leukodystrophy, a rare genetic disorder. HMI-202 showcases Homology Medicines' commitment to developing treatments for diseases with significant unmet needs, utilizing their proprietary platform to advance gene therapy solutions.
HMI-104 is another key product candidate that has completed IND-enabling studies. While the target disorder for HMI-104 is not specified, its development underlines Homology Medicines’ broad approach to tackling various genetic conditions through its advanced gene therapy and editing platform.
